However, in clinical practice, patients with genetic LDLR deficiency do not respond well to PCSK9 mAbs, and for some patients with refractory hypercholesterolemia, the reduction of LDL-C still cannot fully meet their requirements of lipid standards despite current methods. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.